SCHEMBL7199090

SCHEMBL7199090

C[Si](C)(C)Oc1ccc2[c]cccc2c1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7197663 0.86 CYP1A2 (0.33) CYP1A2CYP2A6
SCHEMBL152913 0.80 CYP1A2 (0.55) CYP1A2CYP2A6ACHE
SCHEMBL2213551 0.76 NQO1 (0.43) CYP1A2
Magnesium Chloride Anhydrous SCHEMBL28811729 0.75 CYP1A2 (0.48) CYP1A2CYP2A6ACHE
SCHEMBL27961290 0.75 CYP1A2 (0.48) CYP1A2CYP2A6ACHE
SCHEMBL18207374 0.74 LTA4H (0.43)
SCHEMBL4536269 0.74 CYP1A2 (0.50) CYP1A2CYP2A6
SCHEMBL2253802 0.73 LTA4H (0.42)
SCHEMBL8349506 0.73 ACHE (0.32) ACHE
SCHEMBL5543922 0.72 GPR3 (0.40) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US claimed
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US disclosed
US-20010023296-A1 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer JAPAN POLYCHEM CORPORATION (JP) 2001-09-20 US disclosed
US-6218558-B1 BRIDGED OXYGEN-, NITROGEN- OR SULFUR-CONTAINING METALLOCENE CATALYST CONTAINING AT LEAST CYCLOPENTADIENE RING FUSED TO A C7-10 RING JAPAN POLYCHEM CORPORATION (JP) 2001-04-17 US disclosed
EP-0963996-A2 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer Japan Polychem Corporation (JP) 1999-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023296-A1 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer OSTC, TCP1, COG1 CYP1A2 487/4885CYP2A6 1022/4885ACHE 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.